COVID-19 and Breast Cancer: Analysis of Surgical Management of a Large Referral Center during the 2020-2021 Pandemic Period.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
05 05 2023
Historique:
received: 03 04 2023
revised: 27 04 2023
accepted: 01 05 2023
medline: 29 5 2023
pubmed: 26 5 2023
entrez: 26 5 2023
Statut: epublish

Résumé

Coronavirus disease-19 (COVID-19) has spread worldwide since December 2019 and was officially declared a pandemic in March 2020. Due to the rapid transmission and the high fatality rate, drastic emergency restrictions were issued, with a negative impact on routine clinical activities. In particular, in Italy, many authors have reported a reduction in the number of breast cancer diagnoses and critical problems in the management of patients who accessed the breast units during the dramatic first months of the pandemic. Our study aims to analyze the global impact of COVID-19 in the two years of the pandemic (2020-2021) on the surgical management of breast cancer by comparing them with the previous two years. In our retrospective study, we analyzed all cases of breast cancer diagnosed and surgically treated at the breast unit of "Città della Salute e della Scienza" in Turin, Italy, making a comparison between the 2018-2019 pre-pandemic period and the 2020-2021 pandemic period. We included in our analysis 1331 breast cancer cases surgically treated from January 2018 to December 2021. A total of 726 patients were treated in the pre-pandemic years and 605 in the pandemic period (-121 cases, 9%). No significant differences were observed regarding diagnosis (screening vs. no screening) and timing between radiological diagnosis and surgery for both in situ and invasive tumors. There were no variations in the breast surgical approach (mastectomy vs. conservative surgery), while a reduction in axillary dissection compared to the sentinel lymph node in the pandemic period was observed ( Overall, we report a limited reduction in surgical activity for breast cancer treatment considering the entire pandemic period (2020-2021). These results suggest a prompt resumption of surgical activity similar to the pre-pandemic period.

Sections du résumé

BACKGROUND
Coronavirus disease-19 (COVID-19) has spread worldwide since December 2019 and was officially declared a pandemic in March 2020. Due to the rapid transmission and the high fatality rate, drastic emergency restrictions were issued, with a negative impact on routine clinical activities. In particular, in Italy, many authors have reported a reduction in the number of breast cancer diagnoses and critical problems in the management of patients who accessed the breast units during the dramatic first months of the pandemic. Our study aims to analyze the global impact of COVID-19 in the two years of the pandemic (2020-2021) on the surgical management of breast cancer by comparing them with the previous two years.
METHODS
In our retrospective study, we analyzed all cases of breast cancer diagnosed and surgically treated at the breast unit of "Città della Salute e della Scienza" in Turin, Italy, making a comparison between the 2018-2019 pre-pandemic period and the 2020-2021 pandemic period.
RESULTS
We included in our analysis 1331 breast cancer cases surgically treated from January 2018 to December 2021. A total of 726 patients were treated in the pre-pandemic years and 605 in the pandemic period (-121 cases, 9%). No significant differences were observed regarding diagnosis (screening vs. no screening) and timing between radiological diagnosis and surgery for both in situ and invasive tumors. There were no variations in the breast surgical approach (mastectomy vs. conservative surgery), while a reduction in axillary dissection compared to the sentinel lymph node in the pandemic period was observed (
CONCLUSIONS
Overall, we report a limited reduction in surgical activity for breast cancer treatment considering the entire pandemic period (2020-2021). These results suggest a prompt resumption of surgical activity similar to the pre-pandemic period.

Identifiants

pubmed: 37232817
pii: curroncol30050359
doi: 10.3390/curroncol30050359
pmc: PMC10217661
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4767-4778

Références

Breast Cancer Res Treat. 2016 Jun;157(2):363-371
pubmed: 27155668
Front Oncol. 2020 May 22;10:938
pubmed: 32574281
Oncologist. 2021 Jan;26(1):e66-e77
pubmed: 33044007
BMJ. 2020 Mar 23;368:m1172
pubmed: 32205354
Breast Cancer Res Treat. 2020 Jun;181(3):487-497
pubmed: 32333293
J Clin Oncol. 2021 May 1;39(13):1485-1505
pubmed: 33507815
Curr Breast Cancer Rep. 2021;13(3):103-109
pubmed: 33995839
Sci Rep. 2021 Nov 2;11(1):21526
pubmed: 34728729
J Am Coll Surg. 2020 Oct;231(4):490-496
pubmed: 32673759
Ecancermedicalscience. 2020 Apr 27;14:1027
pubmed: 32368252
Healthcare (Basel). 2020 Dec 03;8(4):
pubmed: 33287260
Anticancer Res. 2021 Sep;41(9):4535-4542
pubmed: 34475080
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Breast. 2022 Oct;65:164-171
pubmed: 35998429
ESMO Open. 2021 Apr;6(2):100055
pubmed: 33582382
Breast Cancer Res Treat. 2021 Jul;188(1):249-258
pubmed: 33651271
J Surg Oncol. 2021 Jan;123(1):24-31
pubmed: 33084056
Br J Cancer. 2020 Feb;122(3):382-387
pubmed: 31780778
Front Surg. 2022 Feb 07;9:811108
pubmed: 35198597
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33080168
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Breast J. 2020 Aug;26(8):1589-1592
pubmed: 32596965
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Br J Surg. 2020 Sep;107(10):e380
pubmed: 32779735
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
Arch Psychiatr Nurs. 2020 Dec;34(6):537-544
pubmed: 33280678
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
NPJ Breast Cancer. 2020 Jun 8;6:21
pubmed: 32550266
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Breast J. 2020 Aug;26(8):1597-1602
pubmed: 32677117
Ann Surg. 2020 Aug;272(2):e96-e97
pubmed: 32675509
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Ann Oncol. 2013 Sep;24(9):2292-7
pubmed: 23709174
Semin Oncol. 2020 Dec;47(6):341-352
pubmed: 33131896
Anticancer Res. 2020 Dec;40(12):7119-7125
pubmed: 33288611
World J Surg. 2020 Nov;44(11):3812-3820
pubmed: 32776194
Breast J. 2006 Jan-Feb;12 Suppl 1:S91-5
pubmed: 16430402
J Health Econ. 2022 Jan;81:102572
pubmed: 34958981
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Ann Oncol. 2021 Apr;32(4):572-573
pubmed: 33444756
EClinicalMedicine. 2020 Sep;26:100523
pubmed: 32984788
Clin Breast Cancer. 2021 Jun;21(3):e165-e167
pubmed: 33419687
Breast Cancer Res Treat. 2022 Nov;196(1):87-95
pubmed: 36018455
Ann Surg Oncol. 2018 Oct;25(10):2829-2838
pubmed: 29968031
In Vivo. 2020 Sep-Oct;34(5):3047-3053
pubmed: 32871851
JCO Oncol Pract. 2020 Oct;16(10):665-674
pubmed: 32603252
Nat Cancer. 2020 Jun;1(6):565-567
pubmed: 35121972

Auteurs

Fulvio Borella (F)

Obstetrics and Gynecology Unit 1, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Luca Bertero (L)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Fabrizia Di Giovanni (F)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Gianluca Witel (G)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Giulia Orlando (G)

Pathology Unit, Department of Oncology, University of Turin, 10126 Turin, Italy.

Alessia Andrea Ricci (AA)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Alessandra Pittaro (A)

Pathology Unit, Città della Salute e della Scienza University Hospital, 10126 Turin, Italy.

Isabella Castellano (I)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Paola Cassoni (P)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH